These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27388873)

  • 1. The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000-2014).
    Turner HC; Bettis AA; Chu BK; McFarland DA; Hooper PJ; Ottesen EA; Bradley MH
    Infect Dis Poverty; 2016 May; 5(1):54. PubMed ID: 27388873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A refined and updated health impact assessment of the Global Programme to Eliminate Lymphatic Filariasis (2000-2020).
    Turner HC; Ottesen EA; Bradley MH
    Parasit Vectors; 2022 May; 15(1):181. PubMed ID: 35643508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007).
    Chu BK; Hooper PJ; Bradley MH; McFarland DA; Ottesen EA
    PLoS Negl Trop Dis; 2010 Jun; 4(6):e708. PubMed ID: 20532228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs.
    Mathew CG; Bettis AA; Chu BK; English M; Ottesen EA; Bradley MH; Turner HC
    Clin Infect Dis; 2020 Jun; 70(12):2561-2567. PubMed ID: 31343064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The global programme to eliminate lymphatic filariasis: health impact after 8 years.
    Ottesen EA; Hooper PJ; Bradley M; Biswas G
    PLoS Negl Trop Dis; 2008 Oct; 2(10):e317. PubMed ID: 18841205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis.
    Kastner RJ; Sicuri E; Stone CM; Matwale G; Onapa A; Tediosi F
    PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005934. PubMed ID: 28949987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investment Success in Public Health: An Analysis of the Cost-Effectiveness and Cost-Benefit of the Global Programme to Eliminate Lymphatic Filariasis.
    Turner HC; Bettis AA; Chu BK; McFarland DA; Hooper PJ; Mante SD; Fitzpatrick C; Bradley MH
    Clin Infect Dis; 2017 Mar; 64(6):728-735. PubMed ID: 27956460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of lymphatic filariasis as a public health problem in Malawi.
    Chiphwanya J; Mkwanda S; Kabuluzi S; Mzilahowa T; Ngwira B; Matipula DE; Chaponda L; Ndhlova P; Katchika P; Mahebere Chirambo C; Moses P; Kumala J; Chiumia M; Barrett C; Betts H; Fahy J; Rebollo Polo M; Reimer L; Stanton MC; Thomas B; Freer S; Molyneux DH; Bockarie MJ; Mackenzie CD; Taylor MJ; Martindale S; Kelly-Hope LA
    PLoS Negl Trop Dis; 2024 Feb; 18(2):e0011957. PubMed ID: 38363794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health economic analyses of the Global Programme to Eliminate Lymphatic Filariasis.
    Turner HC
    Int Health; 2020 Dec; 13(Suppl 1):S71-S74. PubMed ID: 33349885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis.
    Hooper PJ; Chu BK; Mikhailov A; Ottesen EA; Bradley M
    PLoS Negl Trop Dis; 2014 Nov; 8(11):e3333. PubMed ID: 25411843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage.
    Stone CM; Kastner R; Steinmann P; Chitnis N; Tanner M; Tediosi F
    BMJ Glob Health; 2016; 1(1):e000021. PubMed ID: 28588916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Socioeconomic Benefit to Individuals of Achieving the 2020 Targets for Five Preventive Chemotherapy Neglected Tropical Diseases.
    Redekop WK; Lenk EJ; Luyendijk M; Fitzpatrick C; Niessen L; Stolk WA; Tediosi F; Rijnsburger AJ; Bakker R; Hontelez JA; Richardus JH; Jacobson J; de Vlas SJ; Severens JL
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005289. PubMed ID: 28103243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease.
    Ramaiah KD; Ottesen EA
    PLoS Negl Trop Dis; 2014 Nov; 8(11):e3319. PubMed ID: 25412180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Information technology in morbidity management of human lymphatic filariasis-A promising tool in global programme for elimination of lymphatic filariasis.
    Devi RR; Raju V
    J Vector Borne Dis; 2018; 55(1):20-25. PubMed ID: 29916444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs.
    Gedge LM; Bettis AA; Bradley MH; Hollingsworth TD; Turner HC
    Parasit Vectors; 2018 Feb; 11(1):75. PubMed ID: 29391042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of medicine donations in the global programme for the elimination of lymphatic filariasis.
    Williams T; Taylor R; Iwamoto M; Hida T; Gusovsky F
    Int Health; 2020 Dec; 13(Suppl 1):S39-S43. PubMed ID: 33349878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease.
    Lenk EJ; Redekop WK; Luyendijk M; Fitzpatrick C; Niessen L; Stolk WA; Tediosi F; Rijnsburger AJ; Bakker R; Hontelez JAC; Richardus JH; Jacobson J; Le Rutte EA; de Vlas SJ; Severens JL
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006250. PubMed ID: 29534061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neglected tropical diseases: comparison of the costs of integrated and vertical preventive chemotherapy treatment in Niger.
    Leslie J; Garba A; Boubacar K; Yayé Y; Sebongou H; Barkire A; Fleming FM; Mounkaila I; Adamou S; Jackou ML
    Int Health; 2013 Mar; 5(1):78-84. PubMed ID: 24029850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons from lymphatic filariasis elimination and the challenges of post-elimination surveillance in China.
    Fang Y; Zhang Y
    Infect Dis Poverty; 2019 Aug; 8(1):66. PubMed ID: 31387644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging story of disability associated with lymphatic filariasis: a critical review.
    Zeldenryk LM; Gray M; Speare R; Gordon S; Melrose W
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1366. PubMed ID: 22216361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.